Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

Teishima,Jun; Kobatake,Kohei; Hayashi,Tetsutaro; Seno,Yasuyuki; Ikeda,Kenichiro; Nagamatsu,Hirotaka; Hieda,Keisuke; Shoji,Koichi; Miyamoto,Katsutoshi; Inoue,Shogo; Kobayashi,Kanao; Ohara,Shinya; Kajiwara,Mitsuru; Matsubara,Akio

doi:10.3892/ol.2014.2207

Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

Authors:
- Jun Teishima
- Kohei Kobatake
- Tetsutaro Hayashi
- Yasuyuki Seno
- Kenichiro Ikeda
- Hirotaka Nagamatsu
- Keisuke Hieda
- Koichi Shoji
- Katsutoshi Miyamoto
- Shogo Inoue
- Kanao Kobayashi
- Shinya Ohara
- Mitsuru Kajiwara
- Akio Matsubara
View Affiliations

Affiliations: Department of Urology, Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
Published online on: June 2, 2014 https://doi.org/10.3892/ol.2014.2207
Pages: 881-885

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the impact of pre‑treatment C‑reactive protein (CRP) levels on the prediction of prognosis in patients with metastatic renal cell carcinoma (mRCC), who were classified as intermediate‑risk patients using the Memorial Sloan Kettering Cancer Center (MSKCC) risk classification and who received molecular targeted therapy. The oncological outcome of 140 patients with mRCC who underwent molecular targeted therapy was analyzed. Patients were divided into favorable‑, intermediate‑ and poor‑risk groups (groups F, I and P, respectively) based on the MSKCC risk classification. The patients in group I were then further classified into two groups based on pre‑treatment serum CRP levels. The overall survival (OS) rates of the patients in these groups were then assessed. The OS rate of the patients in group I with normal pre‑treatment CRP levels was found to be significantly increased compared with that of patients with high pre‑treatment CRP levels (P<0.0001), while there was no significant difference in the OS rate in the patients with normal pre‑treatment CRP levels in group I compared with those in group F. Multivariate analyses revealed that high pre‑treatment CRP levels were an independent prognostic factor for OS in the patients in group I (P<0.0001; hazard ratio, 3.898). Thus, pre‑treatment CRP levels may be a candidate predictor for OS in patients with intermediate‑risk mRCC.

View Figures

View References

1	Vogl UM, Zehetgruber H, Dominkus M, et al: Prognostic factors in metastatic renal cell carcinoma: metastatectomy as independent prognostic variable. Br J Cancer. 95:691–698. 2006.
2	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med. 356:115–124. 2007.
3	Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 372:449–456. 2008.
4	Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007.
5	Uemura H, Shinohara N, Yuasa T, et al: A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 40:194–202. 2010.
6	Tomita Y, Shinohara N, Yuasa T, et al: Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 40:1166–1172. 2010.
7	Akaza H, Tsukamoto T, Murai M, Nakajima K and Naito S: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 37:755–762. 2007.
8	Tsukamoto T, Shinohara N, Tsuchiya N, et al: Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol. 41:17–24. 2011.
9	Fujisaka Y, Yamada Y, Yamamoto N, et al: A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 40:732–738. 2010.
10	Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 17:2530–2540. 1999.
11	Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20:289–296. 2002.
12	Mekhail TM, Abou-Jawde RM, Boumerhi G, et al: Validation and extention of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 23:832–841. 2005.
13	Naito S, Yamamoto N, Takayama T, et al: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 57:317–325. 2010.
14	Wu Y, Fu X, Zhu X, et al: Prognostic role of systemic inflammatory response in renal cell carcinoma: a systemic review and meta-analysis. J Cancer Res Clin Oncol. 137:887–896. 2011.
15	Johnson TV, Abbasi A, Owen-Smith A, et al: Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol. 183:480–485. 2010.
16	Komai Y, Saito K, Sakai K and Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99:77–80. 2006.
17	Saito K, Tatokoro M, Fujii Y, et al: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol. 55:1145–1153. 2009.
18	Saito K and Kihara K: C-reactive protein as a biomarker for urological cancers. Nat Rev Urol. 8:659–666. 2011.
19	Patil S, Figlin RA, Hutson TE, et al: Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 22:295–300. 2011.
20	Beuselinck B, Oudard S, Rixe O, et al: Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 22:794–800. 2011.
21	Choueiri TK, Xie W, Kollmannsberger C, et al: The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 185:60–66. 2011.
22	Polcari AJ, Gorbonos A, Milner JE and Flanigan RC: The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol. 16:227–233. 2009.
23	Crispen PL and Blute ML: Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep. 13:38–46. 2012.
24	Heikkilä K, Ebrahim S and Lawlor DA: A systemic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 61:824–833. 2007.
25	Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG and McArdle CS: Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 90:1707–1709. 2004.
26	McKeown DJ, Brown DJ, Kelly A, Wallace AM and McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 91:1993–1995. 2004.
27	Yoshida S, Saito K, Koga F, et al: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemotherapy. BJU Int. 101:978–981. 2008.
28	Abramovitch R, Marikovsky M, Meir G and Neeman M: Stimulation of tumour growth by wound-derived growth factors. Br J Cancer. 79:1392–1398. 1999.
29	Miki S, Iwano M, Miki Y, et al: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250:607–610. 1989.